Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| CASTLE BIOSCIENCES INCCSTL · Entity 359 | Director | May 28, 2026 | June 01, 2026 |
| CORCEPT THERAPEUTICS INCCORT · Entity 2620 | Director | February 07, 2019 | February 13, 2019 |
| Equillium, Inc.EQ · Entity 6560 | Director · CHAIRMAN | May 28, 2026 | May 29, 2026 |
| GERON CORPGERN · Entity 4989 | Director | March 29, 2019 | April 01, 2019 |
| ILLUMINA, INC.ILMN · Entity 3137 | Director | May 25, 2017 | May 26, 2017 |
| Vivani Medical, Inc.VANI · Entity 6636 | Director | July 27, 2026 | July 28, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
CASTLE BIOSCIENCES INC
Report date May 28, 2026 · Filed June 01, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 11,766 |
Reported balance
After 2026-05-28 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-05-28 · Grant · Acquired 11,766 · Balance 11,766 F1: Each Restricted Stock Unit ("RSU") represents the right to receive one share of the Issuer's Common Stock. F2: The RSUs vest in full on the earlier of the (a) one-year anniversary of the date on May 28, 2027, or (b) the day immediately preceding the next Annual Meeting of Stockholders following the date of the grant. |
Filing footnotes · ownership attribution and instrument terms
F1: Each Restricted Stock Unit ("RSU") represents the right to receive one share of the Issuer's Common Stock.
F2: The RSUs vest in full on the earlier of the (a) one-year anniversary of the date on May 28, 2027, or (b) the day immediately preceding the next Annual Meeting of Stockholders following the date of the grant.
CORCEPT THERAPEUTICS INC
Report date February 07, 2019 · Filed February 13, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectBioBrit LLC | 130,575 |
Reported balance
After 2019-02-07 transaction · row 1
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 1 · 2019-02-07 · Gift · Disposed 25,000 · Balance 130,575 |
Equillium, Inc.
Report date May 28, 2026 · Filed May 29, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Director stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.84 · Expires 2036-05-27 | Direct | 70,000 |
Reported balance
After 2026-05-28 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-05-28 · Grant · Acquired 70,000 · Balance 70,000 F1: The option vests in twelve equal monthly installments commencing on the grant date of May 28, 2026, provided that the option will, in any case, be fully vested on the date of the Issuer's annual meeting of stockholders following the grant date. |
Filing footnotes · ownership attribution and instrument terms
F1: The option vests in twelve equal monthly installments commencing on the grant date of May 28, 2026, provided that the option will, in any case, be fully vested on the date of the Issuer's annual meeting of stockholders following the grant date.
GERON CORP
Report date March 29, 2019 · Filed April 01, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Commmon StockSEC Table I · non-derivative | IndirectFamily Trust | 51,323 |
Reported balance
After 2019-03-29 transaction · row 1
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 1 · 2019-03-29 · Grant · Acquired 9,036 · Balance 51,323 F1: Shares issued in lieu of cash payment for quarterly board of directors retainer fee. Number of shares issued based on close price on March 29, 2019 of $1.66 per share. |
Filing footnotes · ownership attribution and instrument terms
F1: Shares issued in lieu of cash payment for quarterly board of directors retainer fee. Number of shares issued based on close price on March 29, 2019 of $1.66 per share.
ILLUMINA, INC.
Report date May 25, 2017 · Filed May 26, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 15,324 |
Ending reported balance
After 2017-05-25 transaction · row 3
3 source rows · reconciled sequenceRow 1 · 2017-05-25 · Exercise / conversion · Acquired 600 · Balance 15,924 F1: The sale was made pursuant to a 10b5-1 plan. Row 2 · 2017-05-25 · Sale · Disposed 300 · Balance 15,624 F1: The sale was made pursuant to a 10b5-1 plan. F2: Weighted average sale price representing 300 shares sold ranging from $172.74 to $173.65 per share. Number of shares sold at each separate price will be made available to the SEC staff, the issuer, or a security holder of the issuer upon request. Row 3 · 2017-05-25 · Sale · Disposed 300 · Balance 15,324 F1: The sale was made pursuant to a 10b5-1 plan. F3: Weighted average sale price representing 300 shares sold ranging from $173.82 to $174.09 per share. Number of shares sold at each separate price will be made available to the SEC staff, the issuer, or a security holder of the issuer upon request. |
| Non-qualified Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $71.09 · Expires 2023-05-29 | Direct | 1,600 |
Reported balance
After 2017-05-25 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2017-05-25 · Exercise / conversion · Disposed 600 · Balance 1,600 F1: The sale was made pursuant to a 10b5-1 plan. |
Filing footnotes · ownership attribution and instrument terms
F1: The sale was made pursuant to a 10b5-1 plan.
F2: Weighted average sale price representing 300 shares sold ranging from $172.74 to $173.65 per share. Number of shares sold at each separate price will be made available to the SEC staff, the issuer, or a security holder of the issuer upon request.
F3: Weighted average sale price representing 300 shares sold ranging from $173.82 to $174.09 per share. Number of shares sold at each separate price will be made available to the SEC staff, the issuer, or a security holder of the issuer upon request.
Vivani Medical, Inc.
Report date July 27, 2026 · Filed July 28, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Non-Qualified Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.30 · Expires 2026-07-26 | Direct | 7,965 |
Reported balance
After 2026-07-27 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-07-27 · Grant · Acquired 7,965 · Balance 7,965 F2: Awarded pursuant to the Issuer's non-employee director compensation policy in lieu of cash retainer fees of $8,000, provided in consideration for increased committee service. F1: The stock options have a 10-year term and vests quarterly through December 31, 2026, subject to the Reporting Person's continued service through each such date. |
Filing footnotes · ownership attribution and instrument terms
F1: The stock options have a 10-year term and vests quarterly through December 31, 2026, subject to the Reporting Person's continued service through each such date.
F2: Awarded pursuant to the Issuer's non-employee director compensation policy in lieu of cash retainer fees of $8,000, provided in consideration for increased committee service.
Past disclosures · reporting ended (2)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
INTERCEPT PHARMACEUTICALS, INC.
Report date November 08, 2023 · Filed November 13, 2023
Section 16 reporting ended · disclosed 2023-11-13. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2023-11-08 transaction · row 1
Sequence does not reconcile; account continuity is unresolved.
1 source rowRow 1 · 2023-11-08 · Other · Disposed 23,548 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of September 26, 2023, among the Issuer, Alfasigma S.p.A. ("Alfasigma"), and Interstellar Acquisition Inc., a wholly owned subsidiary of Alfasigma ("Purchaser"), pursuant to which Purchaser completed a tender offer for shares of common stock of the Issuer ("Company Common Stock") and thereafter merged with and into the Issuer, effective as of November 8, 2023 (such date and time of such merger, the "Effective Time"). At the Effective Time, each issued and outstanding share of Company Common Stock was cancelled and converted into the right to receive $19.00 in cash (the "Offer Price") without interest and subject to applicable withholding taxes. |
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2023-11-08 transaction · row 3
Sequence does not reconcile; account continuity is unresolved.
1 source rowRow 3 · 2023-11-08 · Disposition to issuer · Disposed 8,111 · Balance 0 F3: Represents restricted stock units ("RSUs") granted to the Reporting Person. Each RSU represented a contingent right to receive one share of Company Common Stock upon vesting of the RSU. F4: Pursuant to the Merger Agreement, at the Effective Time, each RSU that was outstanding as of immediately prior to the Effective Time was cancelled and converted into the contingent right to receive a cash payment (without interest and subject to any applicable tax withholding) equal to (A) the Offer Price, multiplied by (B) the number of shares of Company Common Stock subject to such RSU. Such payment right will vest and become payable in accordance with vesting schedule (including any vesting acceleration provisions) that applied to the corresponding portion of the applicable RSUs immediately prior to the Effective Time. |
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 0 |
Reported balance
After 2023-11-08 transaction · row 2
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 2 · 2023-11-08 · Other · Disposed 7,812 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of September 26, 2023, among the Issuer, Alfasigma S.p.A. ("Alfasigma"), and Interstellar Acquisition Inc., a wholly owned subsidiary of Alfasigma ("Purchaser"), pursuant to which Purchaser completed a tender offer for shares of common stock of the Issuer ("Company Common Stock") and thereafter merged with and into the Issuer, effective as of November 8, 2023 (such date and time of such merger, the "Effective Time"). At the Effective Time, each issued and outstanding share of Company Common Stock was cancelled and converted into the right to receive $19.00 in cash (the "Offer Price") without interest and subject to applicable withholding taxes. F2: These shares are held by BioBrit, LLC ("BioBrit"). Mr. Bradbury and his spouse are the trustees and beneficiaries of a trust that is the sole member of BioBrit. |
| Option to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $17.08 | Direct | 0 |
Reported balance
After 2023-11-08 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2023-11-08 · Disposition to issuer · Disposed 12,089 · Balance 0 F5: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was less than the Offer Price, was cancelled and converted into the right to receive a cash payment (without interest, and less any applicable withholding taxes) equal to (A) the excess of (x) the Offer Price over (y) the exercise price payable per share of Company Common Stock under such option, multiplied by (B) the total number of shares of Company Common Stock subject to such option immediately prior to the Effective Time. |
| Option to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $16.82 | Direct | 0 |
Reported balance
After 2023-11-08 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2023-11-08 · Disposition to issuer · Disposed 12,790 · Balance 0 F5: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was less than the Offer Price, was cancelled and converted into the right to receive a cash payment (without interest, and less any applicable withholding taxes) equal to (A) the excess of (x) the Offer Price over (y) the exercise price payable per share of Company Common Stock under such option, multiplied by (B) the total number of shares of Company Common Stock subject to such option immediately prior to the Effective Time. |
| Option to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $9.17 | Direct | 0 |
Reported balance
After 2023-11-08 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2023-11-08 · Disposition to issuer · Disposed 12,547 · Balance 0 F5: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was less than the Offer Price, was cancelled and converted into the right to receive a cash payment (without interest, and less any applicable withholding taxes) equal to (A) the excess of (x) the Offer Price over (y) the exercise price payable per share of Company Common Stock under such option, multiplied by (B) the total number of shares of Company Common Stock subject to such option immediately prior to the Effective Time. |
| Option to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $145.22 | Direct | 0 |
Reported balance
After 2023-11-08 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2023-11-08 · Disposition to issuer · Disposed 3,196 · Balance 0 F6: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was equal to or greater than the Offer Price was cancelled with no consideration payable in respect thereof. |
| Option to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $122.01 | Direct | 0 |
Reported balance
After 2023-11-08 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2023-11-08 · Disposition to issuer · Disposed 2,036 · Balance 0 F6: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was equal to or greater than the Offer Price was cancelled with no consideration payable in respect thereof. |
| Option to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $85.12 | Direct | 0 |
Reported balance
After 2023-11-08 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2023-11-08 · Disposition to issuer · Disposed 2,748 · Balance 0 F6: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was equal to or greater than the Offer Price was cancelled with no consideration payable in respect thereof. |
| Option to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $82.25 | Direct | 0 |
Reported balance
After 2023-11-08 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2023-11-08 · Disposition to issuer · Disposed 2,174 · Balance 0 F6: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was equal to or greater than the Offer Price was cancelled with no consideration payable in respect thereof. |
| Option to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $72.74 | Direct | 0 |
Reported balance
After 2023-11-08 transaction · row 11
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 11 · 2023-11-08 · Disposition to issuer · Disposed 2,966 · Balance 0 F6: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was equal to or greater than the Offer Price was cancelled with no consideration payable in respect thereof. |
Filing footnotes · ownership attribution and instrument terms
F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of September 26, 2023, among the Issuer, Alfasigma S.p.A. ("Alfasigma"), and Interstellar Acquisition Inc., a wholly owned subsidiary of Alfasigma ("Purchaser"), pursuant to which Purchaser completed a tender offer for shares of common stock of the Issuer ("Company Common Stock") and thereafter merged with and into the Issuer, effective as of November 8, 2023 (such date and time of such merger, the "Effective Time"). At the Effective Time, each issued and outstanding share of Company Common Stock was cancelled and converted into the right to receive $19.00 in cash (the "Offer Price") without interest and subject to applicable withholding taxes.
F2: These shares are held by BioBrit, LLC ("BioBrit"). Mr. Bradbury and his spouse are the trustees and beneficiaries of a trust that is the sole member of BioBrit.
F3: Represents restricted stock units ("RSUs") granted to the Reporting Person. Each RSU represented a contingent right to receive one share of Company Common Stock upon vesting of the RSU.
F4: Pursuant to the Merger Agreement, at the Effective Time, each RSU that was outstanding as of immediately prior to the Effective Time was cancelled and converted into the contingent right to receive a cash payment (without interest and subject to any applicable tax withholding) equal to (A) the Offer Price, multiplied by (B) the number of shares of Company Common Stock subject to such RSU. Such payment right will vest and become payable in accordance with vesting schedule (including any vesting acceleration provisions) that applied to the corresponding portion of the applicable RSUs immediately prior to the Effective Time.
F5: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was less than the Offer Price, was cancelled and converted into the right to receive a cash payment (without interest, and less any applicable withholding taxes) equal to (A) the excess of (x) the Offer Price over (y) the exercise price payable per share of Company Common Stock under such option, multiplied by (B) the total number of shares of Company Common Stock subject to such option immediately prior to the Effective Time.
F6: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was equal to or greater than the Offer Price was cancelled with no consideration payable in respect thereof.
Nuvation Bio Inc.
Report date February 10, 2021 · Filed February 27, 2021
Section 16 reporting ended · disclosed 2021-02-27. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A Common StockSEC Table I · non-derivative | Direct | 25,000 |
Reported balance
After 2021-02-10 transaction · row 1
1 source rowRow 1 · 2021-02-10 · Exercise / conversion · Acquired 25,000 · Balance 25,000 F1: Each share of Class B Common Stock owned prior to the consummation of the Agreement and Plan of Merger, dated as of October 20, 2020, by and among Panacea Acquisition Corp. ("Panacea"), Panacea Merger Subsidiary Corp., a direct, wholly-owned subsidiary of Panacea ("Merger Sub"), and Nuvation Bio Inc. ("Legacy Nuvation") pursuant to which, as a result of a merger between Legacy Nuvation and Merger Sub, Legacy Nuvation became a direct, wholly-owned subsidiary of Panacea, which subsequently changed its name to Nuvation Bio Inc., was converted into one share of Class A Common Stock; the Class B Common Stock was convertible at any time at the election of the holder (or would have automatically converted at the time of the issuer's initial business combination if not yet converted at such time) with no expiration date. |
| Class B Common StockSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2021-02-10 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2021-02-10 · Exercise / conversion · Disposed 25,000 · Balance 0 F1: Each share of Class B Common Stock owned prior to the consummation of the Agreement and Plan of Merger, dated as of October 20, 2020, by and among Panacea Acquisition Corp. ("Panacea"), Panacea Merger Subsidiary Corp., a direct, wholly-owned subsidiary of Panacea ("Merger Sub"), and Nuvation Bio Inc. ("Legacy Nuvation") pursuant to which, as a result of a merger between Legacy Nuvation and Merger Sub, Legacy Nuvation became a direct, wholly-owned subsidiary of Panacea, which subsequently changed its name to Nuvation Bio Inc., was converted into one share of Class A Common Stock; the Class B Common Stock was convertible at any time at the election of the holder (or would have automatically converted at the time of the issuer's initial business combination if not yet converted at such time) with no expiration date. |
Filing footnotes · ownership attribution and instrument terms
F1: Each share of Class B Common Stock owned prior to the consummation of the Agreement and Plan of Merger, dated as of October 20, 2020, by and among Panacea Acquisition Corp. ("Panacea"), Panacea Merger Subsidiary Corp., a direct, wholly-owned subsidiary of Panacea ("Merger Sub"), and Nuvation Bio Inc. ("Legacy Nuvation") pursuant to which, as a result of a merger between Legacy Nuvation and Merger Sub, Legacy Nuvation became a direct, wholly-owned subsidiary of Panacea, which subsequently changed its name to Nuvation Bio Inc., was converted into one share of Class A Common Stock; the Class B Common Stock was convertible at any time at the election of the holder (or would have automatically converted at the time of the issuer's initial business combination if not yet converted at such time) with no expiration date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 27, 2026 Filed Jul 28, 2026 22:48 UTC | Vivani Medical, Inc. VANI · Entity 6636 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 7,965 | $1.30 Strike: $1.30 | $10,354.50 |
DisclosureSEC source: 0001753926-26-001243 · form4.xml · derivative · entry 1 BRADBURY DANIEL · CIK 0001236397 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,965 Underlying: Common Stock · 7,965 shares Expires 2026-07-26 F2 · price: Awarded pursuant to the Issuer's non-employee director compensation policy in lieu of cash retainer fees of $8,000, provided in consideration for increased committee service. F1 · derivative.exercise_date: The stock options have a 10-year term and vests quarterly through December 31, 2026, subject to the Reporting Person's continued service through each such date. F2 · balance_after: Awarded pursuant to the Issuer's non-employee director compensation policy in lieu of cash retainer fees of $8,000, provided in consideration for increased committee service. Read SEC document |
| June 24, 2026 Filed Jun 25, 2026 23:40 UTC | Vivani Medical, Inc. VANI · Entity 6636 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 36,516 | $1.22 Strike: $1.22 | $44,549.52 |
DisclosureSEC source: 0001753926-26-001069 · form4.xml · derivative · entry 1 BRADBURY DANIEL · CIK 0001236397 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 36,516 Underlying: Common Stock · 36,516 shares Expires 2036-06-23 F2 · price: The option vests in total on the earlier of (i) the first anniversary of the grant or (ii) the next annual meeting of stockholders, subject to continued service through such date. F1 · derivative.exercise_date: Annual grant awarded pursuant to the Issuer's Non-Employee Director Compensation Policy. F2 · derivative.exercise_date: The option vests in total on the earlier of (i) the first anniversary of the grant or (ii) the next annual meeting of stockholders, subject to continued service through such date. F2 · derivative.underlying_shares: The option vests in total on the earlier of (i) the first anniversary of the grant or (ii) the next annual meeting of stockholders, subject to continued service through such date. F2 · balance_after: The option vests in total on the earlier of (i) the first anniversary of the grant or (ii) the next annual meeting of stockholders, subject to continued service through such date. Read SEC document |
| May 28, 2026 Filed May 29, 2026 22:23 UTC | Equillium, Inc. EQ · Entity 6560 | GrantDirector stock option (right to buy) · Derivative | 70,000 | $0.00 Strike: $2.84 | $0.00 |
DisclosureSEC source: 0001236397-26-000003 · form4-05292026_100514.xml · derivative · entry 1 BRADBURY DANIEL · CIK 0001236397 · Director · CHAIRMAN 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 70,000 Underlying: Common Stock · 70,000 shares Expires 2036-05-27 F1 · derivative.exercise_date: The option vests in twelve equal monthly installments commencing on the grant date of May 28, 2026, provided that the option will, in any case, be fully vested on the date of the Issuer's annual meeting of stockholders following the grant date. Read SEC document |
| May 28, 2026 Filed Jun 1, 2026 20:44 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | GrantRestricted Stock Units · Derivative | 11,766 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-26-039554 · wk-form4_1780346654.xml · derivative · entry 1 BRADBURY DANIEL · CIK 0001236397 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,766 Underlying: Common Stock · 11,766 shares Expires not disclosed F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents the right to receive one share of the Issuer's Common Stock. F2 · derivative.exercise_date: The RSUs vest in full on the earlier of the (a) one-year anniversary of the date on May 28, 2027, or (b) the day immediately preceding the next Annual Meeting of Stockholders following the date of the grant. F2 · derivative.expiration_date: The RSUs vest in full on the earlier of the (a) one-year anniversary of the date on May 28, 2027, or (b) the day immediately preceding the next Annual Meeting of Stockholders following the date of the grant. Read SEC document |
| May 22, 2026 Filed May 27, 2026 20:18 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | Exercise / conversionRestricted Stock Units · Derivative | 13,667 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-26-038476 · wk-form4_1779913124.xml · derivative · entry 3 BRADBURY DANIEL · CIK 0001236397 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 13,667 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents the right to receive one share of the Issuer's Common Stock. F3 · derivative.exercise_date: The RSUs vest in full on the earlier of the (a) one-year anniversary of the date on May 22, 2026, or (b) the day immediately preceding the next Annual Meeting of Stockholders following the date of the grant. F3 · derivative.expiration_date: The RSUs vest in full on the earlier of the (a) one-year anniversary of the date on May 22, 2026, or (b) the day immediately preceding the next Annual Meeting of Stockholders following the date of the grant. Read SEC document |
| May 22, 2026 Filed May 27, 2026 20:18 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | Exercise / conversionCommon Stock | 13,667 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001628280-26-038476 · wk-form4_1779913124.xml · nonDerivative · entry 1 BRADBURY DANIEL · CIK 0001236397 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,340 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit ("RSU") represents the right to receive one share of the Issuer's Common Stock. Read SEC document |
| January 01, 2026 Filed Jan 5, 2026 23:50 UTC | Vivani Medical, Inc. VANI · Entity 6636 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 47,212 | $1.23 Strike: $1.23 | $58,070.76 |
DisclosureSEC source: 0001753926-26-000045 · form4.xml · derivative · entry 1 BRADBURY DANIEL · CIK 0001236397 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 47,212 Underlying: Common Stock · 47,212 shares Expires 2035-12-31 F2 · price: Awarded pursuant to the Issuer's non-employee director compensation policy in lieu of cash retainer fees of $45,000. F1 · derivative.exercise_date: The stock options have a 10-year term and vests quarterly through December 31, 2026, subject to the Reporting Person's continued service through each such date. F2 · balance_after: Awarded pursuant to the Issuer's non-employee director compensation policy in lieu of cash retainer fees of $45,000. Read SEC document |
| June 24, 2025 Filed Jun 26, 2025 23:23 UTC | Vivani Medical, Inc. VANI · Entity 6636 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 35,135 | $1.27 Strike: $1.27 | $44,621.45 |
DisclosureSEC source: 0001753926-25-001027 · form4.xml · derivative · entry 1 BRADBURY DANIEL · CIK 0001236397 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 35,135 Underlying: Common Stock · 35,135 shares Expires 2035-06-23 F2 · price: The option vests in total on the earlier of (i) the first anniversary of the grant or (ii) the next annual meeting of stockholders, subject to continued service through such date. F1 · derivative.exercise_date: Annual grant awarded pursuant to the Issuer's Non-Employee Director Compensation Policy. F2 · derivative.exercise_date: The option vests in total on the earlier of (i) the first anniversary of the grant or (ii) the next annual meeting of stockholders, subject to continued service through such date. F2 · derivative.underlying_shares: The option vests in total on the earlier of (i) the first anniversary of the grant or (ii) the next annual meeting of stockholders, subject to continued service through such date. F2 · balance_after: The option vests in total on the earlier of (i) the first anniversary of the grant or (ii) the next annual meeting of stockholders, subject to continued service through such date. Read SEC document |
| May 22, 2025 Filed May 23, 2025 20:19 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | GrantRestricted Stock Units · Derivative | 13,667 | $0.00 | $0.00 |
DisclosureSEC source: 0001447362-25-000084 · wk-form4_1748031546.xml · derivative · entry 4 BRADBURY DANIEL · CIK 0001236397 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,667 Underlying: Common Stock · 13,667 shares Expires not disclosed F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents the right to receive one share of the Issuer's Common Stock. F4 · derivative.exercise_date: The RSUs vest in full on the earlier of the (a) one-year anniversary of the date on May 22, 2026, or (b) the day immediately preceding the next Annual Meeting of Stockholders following the date of the grant. F4 · derivative.expiration_date: The RSUs vest in full on the earlier of the (a) one-year anniversary of the date on May 22, 2026, or (b) the day immediately preceding the next Annual Meeting of Stockholders following the date of the grant. Read SEC document |
| May 21, 2025 Filed May 23, 2025 20:19 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | Exercise / conversionRestricted Stock Units · Derivative | 8,673 | $0.00 | $0.00 |
DisclosureSEC source: 0001447362-25-000084 · wk-form4_1748031546.xml · derivative · entry 3 BRADBURY DANIEL · CIK 0001236397 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 8,673 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents the right to receive one share of the Issuer's Common Stock. F3 · derivative.exercise_date: The RSUs vest in full on the earlier of the (a) one-year anniversary of the date on May 23, 2025, or (b) the day immediately preceding the next Annual Meeting of Stockholders following the date of the grant. F3 · derivative.expiration_date: The RSUs vest in full on the earlier of the (a) one-year anniversary of the date on May 23, 2025, or (b) the day immediately preceding the next Annual Meeting of Stockholders following the date of the grant. Read SEC document |
| May 21, 2025 Filed May 23, 2025 20:19 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | Exercise / conversionCommon Stock | 8,673 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001447362-25-000084 · wk-form4_1748031546.xml · nonDerivative · entry 1 BRADBURY DANIEL · CIK 0001236397 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,673 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit ("RSU") represents the right to receive one share of the Issuer's Common Stock. Read SEC document |
| February 14, 2025 Filed Feb 20, 2025 00:42 UTC | Equillium, Inc. EQ · Entity 6560 | Disposition to issuerEmployee Stock Option (right to buy) · Derivative | 50,000 | Not disclosed Strike: $1.06 | Not disclosed |
DisclosureSEC source: 0001415889-25-004761 · form4-02202025_120229.xml · derivative · entry 12 BRADBURY DANIEL · CIK 0001236397 · Director · EXECUTIVE CHAIRMAN · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 50,000 shares Expires 2033-01-02 F2 · price: On August 7, 2023, the Board of Directors of the Company approved the repricing of certain options based on the closing price of the Company's common stock on August 14, 2023. The repricing of these options was subject to a holding period that lapsed on February 14, 2025. The repricing resulted in the impacted options having a lower exercise price of $0.785 per share, which is the closing price of the Company's common stock on the Nasdaq Capital Market on August 14, 2023. All of the other terms of the options remained unchanged. F1 · derivative.exercise_date: Twenty-five percent of the shares subject to the option vests on the first anniversary of the vesting commencement date, and the remainder vests in 36 equal monthly installments thereafter for the following three years. Read SEC document |
| February 14, 2025 Filed Feb 20, 2025 00:42 UTC | Equillium, Inc. EQ · Entity 6560 | GrantEmployee Stock Option (right to buy) · Derivative | 50,000 | Not disclosed Strike: $0.79 | Not disclosed |
DisclosureSEC source: 0001415889-25-004761 · form4-02202025_120229.xml · derivative · entry 11 BRADBURY DANIEL · CIK 0001236397 · Director · EXECUTIVE CHAIRMAN · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2033-01-02 F2 · price: On August 7, 2023, the Board of Directors of the Company approved the repricing of certain options based on the closing price of the Company's common stock on August 14, 2023. The repricing of these options was subject to a holding period that lapsed on February 14, 2025. The repricing resulted in the impacted options having a lower exercise price of $0.785 per share, which is the closing price of the Company's common stock on the Nasdaq Capital Market on August 14, 2023. All of the other terms of the options remained unchanged. F1 · derivative.exercise_date: Twenty-five percent of the shares subject to the option vests on the first anniversary of the vesting commencement date, and the remainder vests in 36 equal monthly installments thereafter for the following three years. Read SEC document |
| February 14, 2025 Filed Feb 20, 2025 00:42 UTC | Equillium, Inc. EQ · Entity 6560 | Disposition to issuerEmployee Stock Option (right to buy) · Derivative | 38,000 | Not disclosed Strike: $3.59 | Not disclosed |
DisclosureSEC source: 0001415889-25-004761 · form4-02202025_120229.xml · derivative · entry 10 BRADBURY DANIEL · CIK 0001236397 · Director · EXECUTIVE CHAIRMAN · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 38,000 shares Expires 2032-02-29 F2 · price: On August 7, 2023, the Board of Directors of the Company approved the repricing of certain options based on the closing price of the Company's common stock on August 14, 2023. The repricing of these options was subject to a holding period that lapsed on February 14, 2025. The repricing resulted in the impacted options having a lower exercise price of $0.785 per share, which is the closing price of the Company's common stock on the Nasdaq Capital Market on August 14, 2023. All of the other terms of the options remained unchanged. F1 · derivative.exercise_date: Twenty-five percent of the shares subject to the option vests on the first anniversary of the vesting commencement date, and the remainder vests in 36 equal monthly installments thereafter for the following three years. Read SEC document |
| February 14, 2025 Filed Feb 20, 2025 00:42 UTC | Equillium, Inc. EQ · Entity 6560 | GrantEmployee Stock Option (right to buy) · Derivative | 38,000 | Not disclosed Strike: $0.79 | Not disclosed |
DisclosureSEC source: 0001415889-25-004761 · form4-02202025_120229.xml · derivative · entry 9 BRADBURY DANIEL · CIK 0001236397 · Director · EXECUTIVE CHAIRMAN · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 38,000 Underlying: Common Stock · 38,000 shares Expires 2032-02-29 F2 · price: On August 7, 2023, the Board of Directors of the Company approved the repricing of certain options based on the closing price of the Company's common stock on August 14, 2023. The repricing of these options was subject to a holding period that lapsed on February 14, 2025. The repricing resulted in the impacted options having a lower exercise price of $0.785 per share, which is the closing price of the Company's common stock on the Nasdaq Capital Market on August 14, 2023. All of the other terms of the options remained unchanged. F1 · derivative.exercise_date: Twenty-five percent of the shares subject to the option vests on the first anniversary of the vesting commencement date, and the remainder vests in 36 equal monthly installments thereafter for the following three years. Read SEC document |
| February 14, 2025 Filed Feb 20, 2025 00:42 UTC | Equillium, Inc. EQ · Entity 6560 | Disposition to issuerEmployee Stock Option (right to buy) · Derivative | 36,000 | Not disclosed Strike: $5.03 | Not disclosed |
DisclosureSEC source: 0001415889-25-004761 · form4-02202025_120229.xml · derivative · entry 8 BRADBURY DANIEL · CIK 0001236397 · Director · EXECUTIVE CHAIRMAN · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 36,000 shares Expires 2031-01-03 F2 · price: On August 7, 2023, the Board of Directors of the Company approved the repricing of certain options based on the closing price of the Company's common stock on August 14, 2023. The repricing of these options was subject to a holding period that lapsed on February 14, 2025. The repricing resulted in the impacted options having a lower exercise price of $0.785 per share, which is the closing price of the Company's common stock on the Nasdaq Capital Market on August 14, 2023. All of the other terms of the options remained unchanged. F1 · derivative.exercise_date: Twenty-five percent of the shares subject to the option vests on the first anniversary of the vesting commencement date, and the remainder vests in 36 equal monthly installments thereafter for the following three years. Read SEC document |
| February 14, 2025 Filed Feb 20, 2025 00:42 UTC | Equillium, Inc. EQ · Entity 6560 | GrantEmployee Stock Option (right to buy) · Derivative | 36,000 | Not disclosed Strike: $0.79 | Not disclosed |
DisclosureSEC source: 0001415889-25-004761 · form4-02202025_120229.xml · derivative · entry 7 BRADBURY DANIEL · CIK 0001236397 · Director · EXECUTIVE CHAIRMAN · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 36,000 Underlying: Common Stock · 36,000 shares Expires 2031-01-03 F2 · price: On August 7, 2023, the Board of Directors of the Company approved the repricing of certain options based on the closing price of the Company's common stock on August 14, 2023. The repricing of these options was subject to a holding period that lapsed on February 14, 2025. The repricing resulted in the impacted options having a lower exercise price of $0.785 per share, which is the closing price of the Company's common stock on the Nasdaq Capital Market on August 14, 2023. All of the other terms of the options remained unchanged. F1 · derivative.exercise_date: Twenty-five percent of the shares subject to the option vests on the first anniversary of the vesting commencement date, and the remainder vests in 36 equal monthly installments thereafter for the following three years. Read SEC document |
| February 14, 2025 Filed Feb 20, 2025 00:42 UTC | Equillium, Inc. EQ · Entity 6560 | Disposition to issuerEmployee Stock Option (right to buy) · Derivative | 28,708 | Not disclosed Strike: $3.53 | Not disclosed |
DisclosureSEC source: 0001415889-25-004761 · form4-02202025_120229.xml · derivative · entry 6 BRADBURY DANIEL · CIK 0001236397 · Director · EXECUTIVE CHAIRMAN · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 28,708 shares Expires 2030-05-27 F2 · price: On August 7, 2023, the Board of Directors of the Company approved the repricing of certain options based on the closing price of the Company's common stock on August 14, 2023. The repricing of these options was subject to a holding period that lapsed on February 14, 2025. The repricing resulted in the impacted options having a lower exercise price of $0.785 per share, which is the closing price of the Company's common stock on the Nasdaq Capital Market on August 14, 2023. All of the other terms of the options remained unchanged. F3 · derivative.exercise_date: The shares subject to this option became fully vested on the grant date of May 28, 2020. Read SEC document |
| February 14, 2025 Filed Feb 20, 2025 00:42 UTC | Equillium, Inc. EQ · Entity 6560 | GrantEmployee Stock Option (right to buy) · Derivative | 28,708 | Not disclosed Strike: $0.79 | Not disclosed |
DisclosureSEC source: 0001415889-25-004761 · form4-02202025_120229.xml · derivative · entry 5 BRADBURY DANIEL · CIK 0001236397 · Director · EXECUTIVE CHAIRMAN · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 28,708 Underlying: Common Stock · 28,708 shares Expires 2030-05-27 F2 · price: On August 7, 2023, the Board of Directors of the Company approved the repricing of certain options based on the closing price of the Company's common stock on August 14, 2023. The repricing of these options was subject to a holding period that lapsed on February 14, 2025. The repricing resulted in the impacted options having a lower exercise price of $0.785 per share, which is the closing price of the Company's common stock on the Nasdaq Capital Market on August 14, 2023. All of the other terms of the options remained unchanged. F3 · derivative.exercise_date: The shares subject to this option became fully vested on the grant date of May 28, 2020. Read SEC document |
| February 14, 2025 Filed Feb 20, 2025 00:42 UTC | Equillium, Inc. EQ · Entity 6560 | Disposition to issuerEmployee Stock Option (right to buy) · Derivative | 36,000 | Not disclosed Strike: $4.75 | Not disclosed |
DisclosureSEC source: 0001415889-25-004761 · form4-02202025_120229.xml · derivative · entry 4 BRADBURY DANIEL · CIK 0001236397 · Director · EXECUTIVE CHAIRMAN · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 36,000 shares Expires 2029-12-09 F2 · price: On August 7, 2023, the Board of Directors of the Company approved the repricing of certain options based on the closing price of the Company's common stock on August 14, 2023. The repricing of these options was subject to a holding period that lapsed on February 14, 2025. The repricing resulted in the impacted options having a lower exercise price of $0.785 per share, which is the closing price of the Company's common stock on the Nasdaq Capital Market on August 14, 2023. All of the other terms of the options remained unchanged. F1 · derivative.exercise_date: Twenty-five percent of the shares subject to the option vests on the first anniversary of the vesting commencement date, and the remainder vests in 36 equal monthly installments thereafter for the following three years. Read SEC document |
| February 14, 2025 Filed Feb 20, 2025 00:42 UTC | Equillium, Inc. EQ · Entity 6560 | GrantEmployee Stock Option (right to buy) · Derivative | 36,000 | Not disclosed Strike: $0.79 | Not disclosed |
DisclosureSEC source: 0001415889-25-004761 · form4-02202025_120229.xml · derivative · entry 3 BRADBURY DANIEL · CIK 0001236397 · Director · EXECUTIVE CHAIRMAN · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 36,000 Underlying: Common Stock · 36,000 shares Expires 2029-12-09 F2 · price: On August 7, 2023, the Board of Directors of the Company approved the repricing of certain options based on the closing price of the Company's common stock on August 14, 2023. The repricing of these options was subject to a holding period that lapsed on February 14, 2025. The repricing resulted in the impacted options having a lower exercise price of $0.785 per share, which is the closing price of the Company's common stock on the Nasdaq Capital Market on August 14, 2023. All of the other terms of the options remained unchanged. F1 · derivative.exercise_date: Twenty-five percent of the shares subject to the option vests on the first anniversary of the vesting commencement date, and the remainder vests in 36 equal monthly installments thereafter for the following three years. Read SEC document |
| February 14, 2025 Filed Feb 20, 2025 00:42 UTC | Equillium, Inc. EQ · Entity 6560 | Disposition to issuerEmployee Stock Option (right to buy) · Derivative | 90,000 | Not disclosed Strike: $7.16 | Not disclosed |
DisclosureSEC source: 0001415889-25-004761 · form4-02202025_120229.xml · derivative · entry 2 BRADBURY DANIEL · CIK 0001236397 · Director · EXECUTIVE CHAIRMAN · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 90,000 shares Expires 2029-02-12 F2 · price: On August 7, 2023, the Board of Directors of the Company approved the repricing of certain options based on the closing price of the Company's common stock on August 14, 2023. The repricing of these options was subject to a holding period that lapsed on February 14, 2025. The repricing resulted in the impacted options having a lower exercise price of $0.785 per share, which is the closing price of the Company's common stock on the Nasdaq Capital Market on August 14, 2023. All of the other terms of the options remained unchanged. F1 · derivative.exercise_date: Twenty-five percent of the shares subject to the option vests on the first anniversary of the vesting commencement date, and the remainder vests in 36 equal monthly installments thereafter for the following three years. Read SEC document |
| February 14, 2025 Filed Feb 20, 2025 00:42 UTC | Equillium, Inc. EQ · Entity 6560 | GrantEmployee Stock Option (right to buy) · Derivative | 90,000 | Not disclosed Strike: $0.79 | Not disclosed |
DisclosureSEC source: 0001415889-25-004761 · form4-02202025_120229.xml · derivative · entry 1 BRADBURY DANIEL · CIK 0001236397 · Director · EXECUTIVE CHAIRMAN · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 90,000 Underlying: Common Stock · 90,000 shares Expires 2029-02-12 F2 · price: On August 7, 2023, the Board of Directors of the Company approved the repricing of certain options based on the closing price of the Company's common stock on August 14, 2023. The repricing of these options was subject to a holding period that lapsed on February 14, 2025. The repricing resulted in the impacted options having a lower exercise price of $0.785 per share, which is the closing price of the Company's common stock on the Nasdaq Capital Market on August 14, 2023. All of the other terms of the options remained unchanged. F1 · derivative.exercise_date: Twenty-five percent of the shares subject to the option vests on the first anniversary of the vesting commencement date, and the remainder vests in 36 equal monthly installments thereafter for the following three years. Read SEC document |
| February 05, 2025 Filed Feb 7, 2025 21:12 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | SaleCommon Stock | 1,425 | $28.17 | $40,146.53 |
DisclosureSEC source: 0001447362-25-000016 · wk-form4_1738962754.xml · nonDerivative · entry 3 BRADBURY DANIEL · CIK 0001236397 · Director 10b5-1 filing: Plan reported Ownership: Indirect · By Annette Bradbury Irrevocable Descendant's Trust Disclosed balance after: 0 F1 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person, Daniel Bradbury Irrevocable Descendant's Trust, and Annette Bradbury Irrevocable Descendant's Trust on May 10, 2024. F2 · price: This transaction was executed in multiple trades at prices ranging from $28.060 to $28.585, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F5 · ownership.nature: Held by Annette Bradbury Irrevocable Descendant's Trust of which the Reporting Person and his spouse are trustees and their children are beneficiaries. Read SEC document |
| February 05, 2025 Filed Feb 7, 2025 21:12 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | SaleCommon Stock | 1,425 | $28.17 | $40,146.53 |
DisclosureSEC source: 0001447362-25-000016 · wk-form4_1738962754.xml · nonDerivative · entry 2 BRADBURY DANIEL · CIK 0001236397 · Director 10b5-1 filing: Plan reported Ownership: Indirect · By Daniel Bradbury Irrevocable Descendant's Trust Disclosed balance after: 0 F1 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person, Daniel Bradbury Irrevocable Descendant's Trust, and Annette Bradbury Irrevocable Descendant's Trust on May 10, 2024. F2 · price: This transaction was executed in multiple trades at prices ranging from $28.060 to $28.585, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F4 · ownership.nature: Held by Daniel Bradbury Irrevocable Descendant's Trust of which the Reporting Person and his spouse are trustees and their children are beneficiaries. Read SEC document |
| February 05, 2025 Filed Feb 7, 2025 21:12 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | SaleCommon Stock | 5,017 | $28.17 | $141,343.94 |
DisclosureSEC source: 0001447362-25-000016 · wk-form4_1738962754.xml · nonDerivative · entry 1 BRADBURY DANIEL · CIK 0001236397 · Director 10b5-1 filing: Plan reported Ownership: Indirect · By LLC Disclosed balance after: 0 F1 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person, Daniel Bradbury Irrevocable Descendant's Trust, and Annette Bradbury Irrevocable Descendant's Trust on May 10, 2024. F2 · price: This transaction was executed in multiple trades at prices ranging from $28.060 to $28.585, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F3 · ownership.nature: Held by BioBrit, LLC, of which the Reporting Person is the managing member and has voting and investment power over the shares. Read SEC document |
| January 06, 2025 Filed Jan 8, 2025 23:19 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | SaleCommon Stock | 134 | $29.82 | $3,995.88 |
DisclosureSEC source: 0001447362-25-000008 · wk-form4_1736378371.xml · nonDerivative · entry 9 BRADBURY DANIEL · CIK 0001236397 · Director 10b5-1 filing: Plan reported Ownership: Indirect · By Annette Bradbury Irrevocable Descendant's Trust Disclosed balance after: 1,425 F1 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person, Daniel Bradbury Irrevocable Descendant's Trust, and Annette Bradbury Irrevocable Descendant's Trust on May 10, 2024. F7 · price: This transaction was executed in multiple trades at prices ranging from $29.78 to $29.87, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F5 · ownership.nature: Held by Annette Bradbury Irrevocable Descendant's Trust of which the Reporting Person and his spouse are trustees and their children are beneficiaries. Read SEC document |
| January 06, 2025 Filed Jan 8, 2025 23:19 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | SaleCommon Stock | 134 | $29.82 | $3,995.88 |
DisclosureSEC source: 0001447362-25-000008 · wk-form4_1736378371.xml · nonDerivative · entry 8 BRADBURY DANIEL · CIK 0001236397 · Director 10b5-1 filing: Plan reported Ownership: Indirect · By Daniel Bradbury Irrevocable Descendant's Trust Disclosed balance after: 1,425 F1 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person, Daniel Bradbury Irrevocable Descendant's Trust, and Annette Bradbury Irrevocable Descendant's Trust on May 10, 2024. F7 · price: This transaction was executed in multiple trades at prices ranging from $29.78 to $29.87, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F4 · ownership.nature: Held by Daniel Bradbury Irrevocable Descendant's Trust of which the Reporting Person and his spouse are trustees and their children are beneficiaries. Read SEC document |
| January 06, 2025 Filed Jan 8, 2025 23:19 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | SaleCommon Stock | 472 | $29.82 | $14,075.04 |
DisclosureSEC source: 0001447362-25-000008 · wk-form4_1736378371.xml · nonDerivative · entry 7 BRADBURY DANIEL · CIK 0001236397 · Director 10b5-1 filing: Plan reported Ownership: Indirect · By LLC Disclosed balance after: 5,017 F1 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person, Daniel Bradbury Irrevocable Descendant's Trust, and Annette Bradbury Irrevocable Descendant's Trust on May 10, 2024. F7 · price: This transaction was executed in multiple trades at prices ranging from $29.78 to $29.87, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F3 · ownership.nature: Held by BioBrit, LLC, of which the Reporting Person is the managing member and has voting and investment power over the shares. Read SEC document |
| January 06, 2025 Filed Jan 8, 2025 23:19 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | SaleCommon Stock | 857 | $29.41 | $25,204.37 |
DisclosureSEC source: 0001447362-25-000008 · wk-form4_1736378371.xml · nonDerivative · entry 6 BRADBURY DANIEL · CIK 0001236397 · Director 10b5-1 filing: Plan reported Ownership: Indirect · By Annette Bradbury Irrevocable Descendant's Trust Disclosed balance after: 1,559 F1 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person, Daniel Bradbury Irrevocable Descendant's Trust, and Annette Bradbury Irrevocable Descendant's Trust on May 10, 2024. F6 · price: This transaction was executed in multiple trades at prices ranging from $28.84 to $29.77, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F5 · ownership.nature: Held by Annette Bradbury Irrevocable Descendant's Trust of which the Reporting Person and his spouse are trustees and their children are beneficiaries. Read SEC document |
| January 06, 2025 Filed Jan 8, 2025 23:19 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | SaleCommon Stock | 857 | $29.41 | $25,204.37 |
DisclosureSEC source: 0001447362-25-000008 · wk-form4_1736378371.xml · nonDerivative · entry 5 BRADBURY DANIEL · CIK 0001236397 · Director 10b5-1 filing: Plan reported Ownership: Indirect · By Daniel Bradbury Irrevocable Descendant's Trust Disclosed balance after: 1,559 F1 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person, Daniel Bradbury Irrevocable Descendant's Trust, and Annette Bradbury Irrevocable Descendant's Trust on May 10, 2024. F6 · price: This transaction was executed in multiple trades at prices ranging from $28.84 to $29.77, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F4 · ownership.nature: Held by Daniel Bradbury Irrevocable Descendant's Trust of which the Reporting Person and his spouse are trustees and their children are beneficiaries. Read SEC document |
| January 06, 2025 Filed Jan 8, 2025 23:19 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | SaleCommon Stock | 3,015 | $29.41 | $88,671.15 |
DisclosureSEC source: 0001447362-25-000008 · wk-form4_1736378371.xml · nonDerivative · entry 4 BRADBURY DANIEL · CIK 0001236397 · Director 10b5-1 filing: Plan reported Ownership: Indirect · By LLC Disclosed balance after: 5,489 F1 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person, Daniel Bradbury Irrevocable Descendant's Trust, and Annette Bradbury Irrevocable Descendant's Trust on May 10, 2024. F6 · price: This transaction was executed in multiple trades at prices ranging from $28.84 to $29.77, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F3 · ownership.nature: Held by BioBrit, LLC, of which the Reporting Person is the managing member and has voting and investment power over the shares. Read SEC document |
| January 06, 2025 Filed Jan 8, 2025 23:19 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | SaleCommon Stock | 434 | $28.39 | $12,321.26 |
DisclosureSEC source: 0001447362-25-000008 · wk-form4_1736378371.xml · nonDerivative · entry 3 BRADBURY DANIEL · CIK 0001236397 · Director 10b5-1 filing: Plan reported Ownership: Indirect · By Annette Bradbury Irrevocable Descendant's Trust Disclosed balance after: 2,416 F1 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person, Daniel Bradbury Irrevocable Descendant's Trust, and Annette Bradbury Irrevocable Descendant's Trust on May 10, 2024. F2 · price: This transaction was executed in multiple trades at prices ranging from $27.78 to $28.73, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F5 · ownership.nature: Held by Annette Bradbury Irrevocable Descendant's Trust of which the Reporting Person and his spouse are trustees and their children are beneficiaries. Read SEC document |
| January 06, 2025 Filed Jan 8, 2025 23:19 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | SaleCommon Stock | 434 | $28.39 | $12,321.26 |
DisclosureSEC source: 0001447362-25-000008 · wk-form4_1736378371.xml · nonDerivative · entry 2 BRADBURY DANIEL · CIK 0001236397 · Director 10b5-1 filing: Plan reported Ownership: Indirect · By Daniel Bradbury Irrevocable Descendant's Trust Disclosed balance after: 2,416 F1 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person, Daniel Bradbury Irrevocable Descendant's Trust, and Annette Bradbury Irrevocable Descendant's Trust on May 10, 2024. F2 · price: This transaction was executed in multiple trades at prices ranging from $27.78 to $28.73, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F4 · ownership.nature: Held by Daniel Bradbury Irrevocable Descendant's Trust of which the Reporting Person and his spouse are trustees and their children are beneficiaries. Read SEC document |
| January 06, 2025 Filed Jan 8, 2025 23:19 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | SaleCommon Stock | 1,530 | $28.39 | $43,436.70 |
DisclosureSEC source: 0001447362-25-000008 · wk-form4_1736378371.xml · nonDerivative · entry 1 BRADBURY DANIEL · CIK 0001236397 · Director 10b5-1 filing: Plan reported Ownership: Indirect · By LLC Disclosed balance after: 8,504 F1 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person, Daniel Bradbury Irrevocable Descendant's Trust, and Annette Bradbury Irrevocable Descendant's Trust on May 10, 2024. F2 · price: This transaction was executed in multiple trades at prices ranging from $27.78 to $28.73, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F3 · ownership.nature: Held by BioBrit, LLC, of which the Reporting Person is the managing member and has voting and investment power over the shares. Read SEC document |
| January 02, 2025 Filed Jan 6, 2025 23:21 UTC | Equillium, Inc. EQ · Entity 6560 | GrantEmployee Stock Option (right to buy) · Derivative | 50,000 | $0.00 Strike: $0.77 | $0.00 |
DisclosureSEC source: 0001415889-25-000852 · form4-01062025_110151.xml · derivative · entry 1 BRADBURY DANIEL · CIK 0001236397 · Director · EXECUTIVE CHAIRMAN · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2035-01-01 F1 · derivative.exercise_date: Twenty-five percent of the shares subject to the option vests on the first anniversary of the vesting commencement date, and the remainder vests in 36 equal monthly installments thereafter for the following three years. Read SEC document |
| January 01, 2025 Filed Jan 4, 2025 01:06 UTC | Vivani Medical, Inc. VANI · Entity 6636 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 50,059 | $1.16 Strike: $1.16 | $58,068.44 |
DisclosureSEC source: 0001753926-25-000017 · primary_doc.xml · derivative · entry 1 BRADBURY DANIEL · CIK 0001236397 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,059 Underlying: Common Stock · 50,059 shares Expires 2034-12-31 F2 · price: Awarded pursuant to the Issuer's non-employee director compensation policy in lieu of cash retainer fees of $45,000. F1 · derivative.exercise_date: The stock options have a 10-year term and vests quarterly through December 31, 2025, subject to continued service through each such date F2 · balance_after: Awarded pursuant to the Issuer's non-employee director compensation policy in lieu of cash retainer fees of $45,000. Read SEC document |
| January 01, 2025 Filed Jun 26, 2025 23:23 UTC | Vivani Medical, Inc. VANI · Entity 6636 | Disposition to issuerNon-Qualified Stock Option (right to buy) · Derivative | 237 | $1.16 Strike: $1.16 | $274.92 |
DisclosureSEC source: 0001753926-25-001027 · form4.xml · derivative · entry 2 BRADBURY DANIEL · CIK 0001236397 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 49,822 Underlying: Common Stock · 237 shares Expires 2034-12-31 F3 · kind: Reflects an adjustment to a previously reported amount grant on 01/01/2025 from 50,059 to 49,822 due to a clerical error. F3 · shares: Reflects an adjustment to a previously reported amount grant on 01/01/2025 from 50,059 to 49,822 due to a clerical error. F4 · derivative.exercise_date: The option will vest one-fourth at the end of each calendar quarter following the grant date, subject to continued service through each such date. F3 · derivative.underlying_shares: Reflects an adjustment to a previously reported amount grant on 01/01/2025 from 50,059 to 49,822 due to a clerical error. F3 · balance_after: Reflects an adjustment to a previously reported amount grant on 01/01/2025 from 50,059 to 49,822 due to a clerical error. Read SEC document |
| December 03, 2024 Filed Dec 5, 2024 21:28 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | SaleCommon Stock | 99 | $31.32 | $3,100.68 |
DisclosureSEC source: 0001447362-24-000190 · wk-form4_1733434115.xml · nonDerivative · entry 6 BRADBURY DANIEL · CIK 0001236397 · Director 10b5-1 filing: Plan reported Ownership: Indirect · By Annette Bradbury Irrecovable Descendant's Trust Disclosed balance after: 2,850 F1 · kind: The transaction on this Form 4 was made pursuant to a Rule 10b5-1 plan adopted by Daniel Bradbury on May 10, 2024. F6 · price: This transaction was executed in multiple trades at prices ranging from $31.30 to $31.34, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F5 · ownership.nature: Held by Annette Bradbury Irrecovable Descendant's Trust of which the reporting person and his spouse are trustees and their children are beneficiaries. Read SEC document |
| December 03, 2024 Filed Dec 5, 2024 21:28 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | SaleCommon Stock | 99 | $31.32 | $3,100.68 |
DisclosureSEC source: 0001447362-24-000190 · wk-form4_1733434115.xml · nonDerivative · entry 5 BRADBURY DANIEL · CIK 0001236397 · Director 10b5-1 filing: Plan reported Ownership: Indirect · By Daniel Bradbury Irrecovable Descendant's Trust Disclosed balance after: 2,850 F1 · kind: The transaction on this Form 4 was made pursuant to a Rule 10b5-1 plan adopted by Daniel Bradbury on May 10, 2024. F6 · price: This transaction was executed in multiple trades at prices ranging from $31.30 to $31.34, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F4 · ownership.nature: Held by Daniel Bradbury Irrecovable Descendant's Trust of which the reporting person and his spouse are trustees and their children are beneficiaries. Read SEC document |
| December 03, 2024 Filed Dec 5, 2024 21:28 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | SaleCommon Stock | 348 | $31.32 | $10,899.36 |
DisclosureSEC source: 0001447362-24-000190 · wk-form4_1733434115.xml · nonDerivative · entry 4 BRADBURY DANIEL · CIK 0001236397 · Director 10b5-1 filing: Plan reported Ownership: Indirect · By LLC Disclosed balance after: 10,034 F1 · kind: The transaction on this Form 4 was made pursuant to a Rule 10b5-1 plan adopted by Daniel Bradbury on May 10, 2024. F6 · price: This transaction was executed in multiple trades at prices ranging from $31.30 to $31.34, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F3 · ownership.nature: Held by BioBrit, LLC, of which the Reporting Person is the managing member and has voting and investment power over the shares. Read SEC document |
| December 03, 2024 Filed Dec 5, 2024 21:28 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | SaleCommon Stock | 1,326 | $30.95 | $41,041.03 |
DisclosureSEC source: 0001447362-24-000190 · wk-form4_1733434115.xml · nonDerivative · entry 3 BRADBURY DANIEL · CIK 0001236397 · Director 10b5-1 filing: Plan reported Ownership: Indirect · By Annette Bradbury Irrecovable Descendant's Trust Disclosed balance after: 2,949 F1 · kind: The transaction on this Form 4 was made pursuant to a Rule 10b5-1 plan adopted by Daniel Bradbury on May 10, 2024. F2 · price: This transaction was executed in multiple trades at prices ranging from $30.300 to $31.275, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F5 · ownership.nature: Held by Annette Bradbury Irrecovable Descendant's Trust of which the reporting person and his spouse are trustees and their children are beneficiaries. Read SEC document |
| December 03, 2024 Filed Dec 5, 2024 21:28 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | SaleCommon Stock | 1,326 | $30.95 | $41,041.03 |
DisclosureSEC source: 0001447362-24-000190 · wk-form4_1733434115.xml · nonDerivative · entry 2 BRADBURY DANIEL · CIK 0001236397 · Director 10b5-1 filing: Plan reported Ownership: Indirect · By Daniel Bradbury Irrecovable Descendant's Trust Disclosed balance after: 2,949 F1 · kind: The transaction on this Form 4 was made pursuant to a Rule 10b5-1 plan adopted by Daniel Bradbury on May 10, 2024. F2 · price: This transaction was executed in multiple trades at prices ranging from $30.300 to $31.275, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F4 · ownership.nature: Held by Daniel Bradbury Irrecovable Descendant's Trust of which the reporting person and his spouse are trustees and their children are beneficiaries. Read SEC document |
| December 03, 2024 Filed Dec 5, 2024 21:28 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | SaleCommon Stock | 4,669 | $30.95 | $144,510.22 |
DisclosureSEC source: 0001447362-24-000190 · wk-form4_1733434115.xml · nonDerivative · entry 1 BRADBURY DANIEL · CIK 0001236397 · Director 10b5-1 filing: Plan reported Ownership: Indirect · By LLC Disclosed balance after: 10,382 F1 · kind: The transaction on this Form 4 was made pursuant to a Rule 10b5-1 plan adopted by Daniel Bradbury on May 10, 2024. F2 · price: This transaction was executed in multiple trades at prices ranging from $30.300 to $31.275, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F3 · ownership.nature: Held by BioBrit, LLC, of which the Reporting Person is the managing member and has voting and investment power over the shares. Read SEC document |
| November 01, 2024 Filed Nov 5, 2024 21:32 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | SaleCommon Stock | 287 | $35.33 | $10,139.71 |
DisclosureSEC source: 0001447362-24-000172 · wk-form4_1730842347.xml · nonDerivative · entry 9 BRADBURY DANIEL · CIK 0001236397 · Director 10b5-1 filing: Plan reported Ownership: Indirect · By Annette Bradbury Irrecovable Descendant's Trust Disclosed balance after: 4,275 F1 · kind: The transaction on this Form 4 was made pursuant to a Rule 10b5-1 plan adopted by Daniel Bradbury on May 10, 2024. F7 · price: This transaction was executed in multiple trades at prices ranging from $35.31 to $35.38, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F5 · ownership.nature: Held by Annette Bradbury Irrecovable Descendant's Trust of which the reporting person and his spouse are trustees and their children are beneficiaries. Read SEC document |
| November 01, 2024 Filed Nov 5, 2024 21:32 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | SaleCommon Stock | 287 | $35.33 | $10,139.71 |
DisclosureSEC source: 0001447362-24-000172 · wk-form4_1730842347.xml · nonDerivative · entry 8 BRADBURY DANIEL · CIK 0001236397 · Director 10b5-1 filing: Plan reported Ownership: Indirect · By Daniel Bradbury Irrecovable Descendant's Trust Disclosed balance after: 4,275 F1 · kind: The transaction on this Form 4 was made pursuant to a Rule 10b5-1 plan adopted by Daniel Bradbury on May 10, 2024. F7 · price: This transaction was executed in multiple trades at prices ranging from $35.31 to $35.38, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F4 · ownership.nature: Held by Daniel Bradbury Irrecovable Descendant's Trust of which the reporting person and his spouse are trustees and their children are beneficiaries. Read SEC document |
| November 01, 2024 Filed Nov 5, 2024 21:32 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | SaleCommon Stock | 1,009 | $35.33 | $35,647.97 |
DisclosureSEC source: 0001447362-24-000172 · wk-form4_1730842347.xml · nonDerivative · entry 7 BRADBURY DANIEL · CIK 0001236397 · Director 10b5-1 filing: Plan reported Ownership: Indirect · By LLC Disclosed balance after: 15,051 F1 · kind: The transaction on this Form 4 was made pursuant to a Rule 10b5-1 plan adopted by Daniel Bradbury on May 10, 2024. F7 · price: This transaction was executed in multiple trades at prices ranging from $35.31 to $35.38, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F3 · ownership.nature: Held by BioBrit, LLC, of which the Reporting Person is the managing member and has voting and investment power over the shares. Read SEC document |
| November 01, 2024 Filed Nov 5, 2024 21:32 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | SaleCommon Stock | 763 | $34.92 | $26,643.96 |
DisclosureSEC source: 0001447362-24-000172 · wk-form4_1730842347.xml · nonDerivative · entry 6 BRADBURY DANIEL · CIK 0001236397 · Director 10b5-1 filing: Plan reported Ownership: Indirect · By Annette Bradbury Irrecovable Descendant's Trust Disclosed balance after: 4,562 F1 · kind: The transaction on this Form 4 was made pursuant to a Rule 10b5-1 plan adopted by Daniel Bradbury on May 10, 2024. F6 · price: This transaction was executed in multiple trades at prices ranging from $34.35 to $35.30, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F5 · ownership.nature: Held by Annette Bradbury Irrecovable Descendant's Trust of which the reporting person and his spouse are trustees and their children are beneficiaries. Read SEC document |
| November 01, 2024 Filed Nov 5, 2024 21:32 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | SaleCommon Stock | 763 | $34.92 | $26,643.96 |
DisclosureSEC source: 0001447362-24-000172 · wk-form4_1730842347.xml · nonDerivative · entry 5 BRADBURY DANIEL · CIK 0001236397 · Director 10b5-1 filing: Plan reported Ownership: Indirect · By Daniel Bradbury Irrecovable Descendant's Trust Disclosed balance after: 4,562 F1 · kind: The transaction on this Form 4 was made pursuant to a Rule 10b5-1 plan adopted by Daniel Bradbury on May 10, 2024. F6 · price: This transaction was executed in multiple trades at prices ranging from $34.35 to $35.30, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F4 · ownership.nature: Held by Daniel Bradbury Irrecovable Descendant's Trust of which the reporting person and his spouse are trustees and their children are beneficiaries. Read SEC document |
| November 01, 2024 Filed Nov 5, 2024 21:32 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | SaleCommon Stock | 2,686 | $34.92 | $93,795.12 |
DisclosureSEC source: 0001447362-24-000172 · wk-form4_1730842347.xml · nonDerivative · entry 4 BRADBURY DANIEL · CIK 0001236397 · Director 10b5-1 filing: Plan reported Ownership: Indirect · By LLC Disclosed balance after: 16,060 F1 · kind: The transaction on this Form 4 was made pursuant to a Rule 10b5-1 plan adopted by Daniel Bradbury on May 10, 2024. F6 · price: This transaction was executed in multiple trades at prices ranging from $34.35 to $35.30, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F3 · ownership.nature: Held by BioBrit, LLC, of which the Reporting Person is the managing member and has voting and investment power over the shares. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.